Overview of Ilvico N

Property	Description
Active ingredients	Acetaminophen, Brompheniramine, Caffeine, Sodium Ascorbate
Form	Oral tablet
Pharmacological class	Analgesic, Antipyretic, H₁ Antihistamine, CNS Stimulant Combination
General purpose	Symptomatic relief of common cold and flu discomforts
Origin	Synthetic/Derived Combination

What Type of Medicine is Ilvico N?

Ilvico N is classified as a fixed-dose combination product designed for the symptomatic relief of acute discomforts associated with the common cold and influenza. This multi-component medicine belongs to the general pharmacological class of complex cold and flu remedies and is supplied as an oral tablet for systemic action within the body. The preparation is considered synthetic/derived, combining multiple synthesized chemical entities and a synthesized nutrient salt into a single formulation. The overall identity is centered on providing integrated management for the variety of symptoms that typically accompany upper respiratory tract infections. The combination of analgesics and antihistamines is a strategy clinically recognized for managing the diverse symptom profile of upper respiratory illness which confirms that combining these substance classes is an established approach to ease the discomfort caused by acute respiratory infection.

The Four Active Ingredients in Ilvico N

The pharmacological core of Ilvico N consists of four distinct active ingredients with established functions. Acetaminophen acts as a non-opioid analgesic and antipyretic, utilized worldwide for the treatment of pain and fever. Brompheniramine is a first-generation H₁ antihistamine chosen to alleviate symptoms like sneezing and runny nose driven by histamine release. The formula also incorporates Caffeine, which functions as a mild central nervous system stimulant to help counteract the fatigue often associated with illness. Finally, Sodium Ascorbate provides a source of Vitamin C (ascorbic acid), an essential micronutrient. The inclusion of Vitamin C, specifically, is often employed in such preparations due to its role as an antioxidant and essential cofactor in various physiological processes which indicates that the Sodium Ascorbate component supports general bodily function during the period of acute illness.

General Purpose and Integrated Benefit

The general purpose of Ilvico N is to achieve integrated, broad-spectrum symptomatic management for a multi-faceted illness, such as when a person experiences both a fever and a runny nose simultaneously. The fixed combination is specifically formulated to ensure that different classes of discomfort—pain, fever, nasal irritation, and lethargy—are addressed concurrently. By delivering these four agents with distinct, yet complementary, actions, the preparation’s benefit lies in its ability to offer a comprehensive profile of relief across the complex symptomatology of acute upper respiratory tract infections.

Regulatory References

What side effects are possible with Ilvico N ?

Possible Side Effects and Safety Information

Official regulatory documents classify the adverse reactions associated with the components of this medicine into various categories and physiological systems, including Hepatobiliary Disorders (liver), Nervous System Disorders, and Gastrointestinal Disorders. The safety profile is defined by both common and serious potential effects.

Commonly Documented Adverse Reactions are often linked to the antihistamine component, Brompheniramine, and include drowsiness, dry mouth, dizziness, and sedation [Source 2.1, 1.2]. Effects such as restlessness, insomnia, and palpitations are associated with the stimulant component, Caffeine [Source 2.1, 1.7].

Serious Adverse Reactions are specifically highlighted in regulatory labeling. The most critical risk is Acute Liver Failure or hepatic necrosis, associated with the Acetaminophen component, often resulting from exceeding the maximum recommended daily dose or concurrent use of other acetaminophen-containing products [Source 1.1, 1.7]. Rare cases of severe skin reactions, such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), have also been documented [Source 1.5, 1.7].

Safety-Related Restrictions include the mandatory caution against using this medicine with any other product containing acetaminophen to prevent severe liver damage [Source 1.7]. Due to the Brompheniramine component, the medicine may impair mental alertness and the ability to drive or operate machinery [Source 2.1, 1.6]. Safety considerations are also noted for older adults, who may experience increased susceptibility to side effects like confusion and urinary retention [Source 1.6, 2.1].

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documents define the overdose risk for this product primarily through the toxicity of the paracetamol component, which can lead to irreversible liver damage.

Documented Overdose Profile

Overdose Domain	Clinical Manifestation or Risk (as stated in label)
Anticipated Symptoms	Early symptoms may include agitation, malaise, diarrhea, abdominal pain, nausea, vomiting, loss of appetite, dizziness, drowsiness, disorientation, and excessive sweating.
Serious Complications	The most severe risk is delayed, serious liver damage (hepatotoxicity), which may not manifest until three days after ingestion, even in cases of severe poisoning. Other risks include lack of muscular coordination and tingling/numbness.
High-Risk Populations	Patients who are chronic alcoholics or who are taking barbiturates are cited in labeling as having a potentially increased susceptibility to the paracetamol toxicity of an overdose.

Required Emergency Action

IMMEDIATE MEDICAL ADVICE SHOULD BE SOUGHT IN THE EVENT OF OVERDOSAGE EVEN IF YOU FEEL WELL because of the risk of delayed, serious liver damage. Overdose is considered a risk of severe poisoning and requires urgent professional medical management.

If an overdose is suspected, one must immediately go to a medical center or call a Toxicological Information Service. Taking the product packaging is recommended to inform healthcare providers. Medical treatment for overdose is generally most effective if started within four hours of the ingestion.

Therapeutic Uses of Ilvico N

What Ilvico N Treats: Main Uses and Benefits

Ilvico N is commonly used across conditions presenting with acute episodes of the common cold and flu, applied across domains where additional symptomatic support is needed. These types of products combine agents to address various symptoms like aches, fever, sneezing, and runny nose, which may be part of symptomatic management.

The medication is commonly used to help with symptom clusters that may become intense or disruptive, primarily by supporting the management of symptoms related to systemic imbalance and fever. It is relevant for easing systemic discomforts, including body aches, muscle pain, and headache, and is commonly used to help with fever. The primary benefit supports the patient during difficult episodes by easing distress across multiple symptom domains. This benefit supports the ability to manage concurrent manifestations like catarrhal irritation and illness-related fatigue, assisting with maintaining functional stability when symptoms interfere with routine activities.

Quick Fact: Relief for Multi-Symptom Discomfort The combination is applied in scenarios where patients need supportive relief from the concurrent presence of fever, pain, and upper respiratory symptoms.

Furthermore, it is applied in addressing nasal and catarrhal irritation, such as a runny nose and sneezing, which contributes to improved day-to-day comfort. The formula also provides supportive relief against illness-related fatigue often associated with acute sickness.

Regulatory References

NIH MedlinePlus overview of cold and cough medicines

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Ilvico N — Official Regulatory Information

Eligibility scope

Population Status	Eligibility Rule (as stated in label)
Permitted Use	Adults and adolescents aged 12 years and older under standard labeled conditions.
Contraindicated	Children under 12 years of age; patients with severe liver or kidney impairment; narrow-angle glaucoma; tachyarrhythmias; G6PD deficiency; haemophilia; or hypersensitivity to components.
Not Recommended	Pregnant and breastfeeding women (unless under medical advice).
Caution Required	Older adults; patients with prostate enlargement or vesical neck obstruction; hyperthyroidism; chronic alcoholism; or mild-to-moderate hepatic impairment.

Eligibility classifications (high-level)

Eligibility severity classification: Formal categories range from Contraindicated (strictly prohibited, e.g., severe organ disease) to Permitted (allowed under standard conditions) and Use with Caution (requiring special consideration, e.g., in the elderly).
Regulatory basis: The criteria are grounded in official regulatory documents such as the Summary of Product Characteristics (SmPC) used by national health agencies.

Resulting eligibility structure

Official regulatory documentation formally establishes that Ilvico N is permitted for individuals aged 12 and above. Use is strictly prohibited in defined populations such as those with severe kidney or liver disease, certain heart rhythm disorders, and specific genetic conditions. Other populations, including pregnant women and the elderly, are classified as requiring conditional use or avoidance, defining the regulatory boundaries for population eligibility.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Ilvico N documents interactions primarily related to the combined effects of its active components: Acetaminophen, Brompheniramine, and Caffeine.

Documented Interaction Patterns

Interaction Type	Interacting Substances/Classes	Official Regulatory Statement
Formal Contraindication	Monoamine Oxidase Inhibitors (MAOIs)	Co-administration is contraindicated due to the potential to prolong and intensify the anticholinergic effects of the antihistamine component.
Pharmacodynamic Risk	Alcohol, other CNS Depressants (e.g., Sedatives)	These substances may have additive central depressant effects with Brompheniramine, potentiating sedation.
Exposure Modification	Anticoagulants (e.g., Warfarin)	Acetaminophen may potentiate the anticoagulant effect over time, which can lead to an increase in the International Normalized Ratio (INR).
Absorption Rate	Gastric Motility Agents	Accelerants like Metoclopramide increase the rate of Acetaminophen absorption, while agents that slow motility reduce it.
Metabolic Risk	Liver Enzyme Inducers, Chronic Alcohol Abuse	Both Liver Enzyme Inducers and chronic alcohol abuse (three or more drinks daily) increase the hepatotoxic potential of Acetaminophen.

Regulatory documents highlight that the combined antihistamine component requires careful consideration with other sedating agents, defining a context of additive CNS effects. Furthermore, the regulatory guidance emphasizes the constraints imposed by the Acetaminophen component regarding metabolism-related toxicity risks and its documented effects on blood-clotting measures with Warfarin. Salicylamide is also noted as prolonging the elimination half-life of Acetaminophen.

Mechanism of Action

How Ilvico N Works

The action of the components is described by the independent and convergent modulation of three distinct biological signaling systems.

Central Modulation of Fever and Pain Pathways

This domain involves Acetaminophen's action, which inhibits specific Cyclooxygenase (COX) isoforms primarily in the brain. This enzyme inhibition reduces the synthesis of prostaglandins ( PGE2) in the hypothalamus, the center for temperature control. This molecular step allows for a lowering of the elevated thermal set-point, which promotes systemic heat dissipation and a modification of central nociceptive signaling.

Antagonism of Histamine-Driven Nasal Responses

This section addresses the mechanism of Brompheniramine, which acts as an antagonist at the Histamine H1 Receptors ( H1 R). By blocking these receptors, the drug interferes with the signaling cascade initiated by the mediator histamine, which is responsible for increasing capillary permeability and glandular secretion. This antagonism influences glandular secretion and vascular permeability, leading to a modification of nasal fluid dynamics.

Reversing CNS Inhibition and Mechanistic Synergy

The formula includes Caffeine, which functions as a non-selective antagonist at Adenosine Receptors in the brain. Since adenosine acts as a natural inhibitory neuromodulator, its receptor blockade removes this inhibitory influence on neuronal activity, leading to an enhanced cortical activity state. Furthermore, this action exhibits mechanistic counter-regulation against the sedative property inherent to the antihistamine component's central activity.

Dosage and Administration Information

Official Administration Protocol

The usage of Ilvico N is defined by a standardized set of instructions that govern its administration, frequency, and duration. The medication is delivered via the oral route as a fixed-dose tablet.

Dosing and Frequency

The established dose for adults and adolescents 12 years of age and older is one or two tablets per administration. Dosing is permitted up to three times daily, strictly separated by a minimum interval of 8 hours. Guidelines mandate that the total daily intake must not exceed 6 tablets in a 24-hour period, which represents the maximum permitted dosage for the combined active ingredients.

Administration Conditions and Constraints

The tablet must be swallowed whole with water or a suitable liquid. Standard instructions specify that administration is preferably after meals (postprandially). The entire course of treatment is limited to short-term use only, and administration must be discontinued once symptoms subside, typically not exceeding 5 days without subsequent re-evaluation. If a dose is missed, it should be taken as soon as remembered, ensuring the 8-hour interval is maintained before the next dose, without ever taking a double dose to compensate.

Furthermore, the protocol requires strict adherence to one crucial procedural constraint: the product must not be taken concurrently with any other medicinal product containing Paracetamol (Acetaminophen).

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ilvico N

Evidence for Symptomatic Relief of the Common Cold and Flu-like Syndromes

The research base for fixed-dose combinations containing an analgesic (like acetaminophen) and an antihistamine (like brompheniramine) was studied for the temporary management of discomforts associated with acute upper respiratory infections. This includes conditions characterized by fluctuating or episodic manifestations, such as the common cold or flu-like syndromes. Randomized Controlled Trials (RCTs) and Systematic Reviews are the primary sources of evidence used in research exploring how symptoms change over time.

Researchers monitored patient-reported outcomes describing perceived discomfort related to physical discomfort like headache, body aches, and fever. The evidence contributes to understanding symptom patterns during periods of heightened symptom activity. Studies reported measurements of changes in symptom severity scores, indicating that the combinations was evaluated in the context of temporary, concurrent symptom management.

Focus of Clinical Studies: Measured Outcomes and Trial Designs

The trials relevant to Ilvico N’s ingredients often focused on outcomes related to systemic or functional imbalance experienced during acute sickness. Specifically, research examined how combinations of these agents affect the measured intensity of individual symptoms like pain, fever, sneezing, and runny nose (rhinorrhea). In addition to measuring symptom changes, studies were used in observational settings evaluating daily-life functioning.

The findings describe patterns observed in the studies over short observation intervals. However, Findings concerning the measured changes in symptom metrics were heterogeneous across different systematic reviews, largely because the scales used in studies examining symptom intensity or variability were not always uniform. Research provides insight into short-term changes in these symptoms when the combination of ingredients was evaluated in adult populations.

Short-Term Follow-up and Extended Use Evidence

The research focusing on fixed-dose combination cold remedies primarily involves studies conducted during periods of increased symptom activity that lasted only for a few days. Therefore, the follow-up durations were limited, typically examining patient responses over intervals of 48 hours to 7 days. This research explores short-term symptom changes during the peak acute phase of the illness.

Because the focus of the available research is centered on acute symptom management, there is limited information for long-term outcomes or durability of effect. The evidence does not fully characterize the consequences of using these combination products repeatedly or intermittently over extended periods, and research is ongoing in this area.

Research in Specific Patient Groups

The research generally includes individuals aged 18 and older who are otherwise healthy and experiencing cold or flu symptoms. Consequently, the results apply only to the populations studied. Data for certain groups remain insufficient. For instance, evidence is limited from dedicated studies focusing specifically on older adults (those over 65 years) or individuals with complex pre-existing medical conditions (comorbidities). Therefore, data for these groups remain insufficient when examining symptom patterns and measured responses.

Gaps and Areas of Research Uncertainty

The research contributes to the broader evidence landscape, yet evidence highlights what is known—and what is still uncertain. One key limitation is that sample sizes were modest in some of the individual trials aggregated in systematic reviews. Furthermore, evidence quality varies across studies, and the heterogeneity of measurement tools used in evidence describing how symptoms are measured can limit the ability to draw universally consistent conclusions across all aggregated data sets.

The evidence describes group patterns, not personal outcomes, meaning research does not determine whether an individual will respond similarly. Because comparative evidence is lacking for many specific multi-ingredient formulations, the research provides context but not individual predictions about measured symptom patterns. Subgroup findings are uncertain, as the main focus of trials was evaluated in the general adult population.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Ilvico N (FAQ)

Q: Can you take Ilvico N right before going to bed?

A: Regulatory documents list the side effects of Ilvico N, noting that the medication contains Caffeine, a stimulant, which is associated with side effects like restlessness and insomnia (difficulty in sleeping). While the antihistamine component can cause drowsiness, the stimulant effect may counteract it. This effect is a factor that individuals may need to consider when planning evening use.

Q: Is a slight headache a normal side effect when starting Ilvico N?

A: According to official safety information for this medicine, headache is listed as one of the commonly reported side effects. If concerns about side effects arise, individuals should consult the relevant professional as detailed in the official package leaflet.

Q: Can people with asthma use Ilvico N?

A: Official precautions advise consulting a healthcare professional before using this medicine if they have pre-existing lung or heart disorders. This general caution indicates that individuals with respiratory conditions like asthma typically need to consult a healthcare professional regarding suitability.

Q: Why do some people say Ilvico N makes them feel jittery?

A: Ilvico N contains Caffeine, which functions as a central nervous system stimulant. The feeling of being 'jittery' is likely related to the stimulant action, as official safety information lists side effects associated with this component, including restlessness, palpitations (a fluttering or racing heart), and insomnia.

Q: Can Ilvico N interact with common allergy medicines (antihistamines)?

A: The official product information notes that using this medicine with other drugs that cause central nervous system depression may increase side effects like sedation and impaired alertness. The presence of an antihistamine in this formulation means co-administration with other similar agents may present a risk of additive central depressant effects, as noted in the drug information.

Q: Is it safe to use other decongestants alongside Ilvico N?

A: Official drug information cautions that the combination of Ilvico N with certain other medicines, including some decongestants, may present an increased risk of specific side effects, such as a rise in blood pressure, or enhanced anticholinergic effects like urinary retention. Therefore, using other decongestants concurrently typically requires professional consultation.

Q: Does Ilvico N help with body aches and fever associated with the flu?

A: Yes, official indications state that the medicine is used for the symptomatic relief of discomforts associated with colds and flu. The analgesic component is intended to relieve headache, minor aches and pains, and fever.

Q: Can people with liver issues take a reduced amount of Ilvico N?

A: Official regulatory documents state that the medicine is contraindicated (strictly prohibited) for patients with severe liver impairment. In cases of mild-to-moderate liver impairment, a healthcare professional typically needs to assess the need for a lower daily dose.

Q: Is the onset of action different when Ilvico N is taken on an empty stomach?

A: Official administration instructions specify that the medicine should be taken preferably after meals (postprandially). The preference for taking the medicine after meals is noted to support consistent absorption of the components and may help to reduce the potential for gastrointestinal upset.

Q: Why is Ilvico N sometimes recommended over single-ingredient pain relievers for colds?

A: According to official product information, this is a fixed-dose combination indicated for the relief of multiple symptoms associated with colds and flu. The combination is formulated to provide an integrated approach to manage the varied symptoms, such as pain, fever, and nasal irritation, concurrently.

Q: Can Ilvico N cause stomach upset or nausea?

A: Official safety documents list stomach pain as a possible side effect of the medicine. General gastrointestinal disturbance has also been reported in studies, which may include feelings of nausea or a general stomach upset.

Q: Can older adults (over 65) typically use Ilvico N?

A: Yes, but use in the elderly is specifically listed as requiring caution in official warnings. This is because older adults may be more susceptible to certain side effects, such as confusion and urinary retention, and may be subject to specific dosing recommendations from a healthcare professional.

Q: Can someone with kidney problems take Ilvico N?

A: The product is contraindicated (must not be used) for patients who have severe kidney impairment. Individuals with mild-to-moderate kidney impairment should typically seek professional assessment, as use with caution or adjustment of the dosage may be necessary.

Q: Is there any research on the safety of Ilvico N during breastfeeding?

A: Official regulatory documents classify the medicine as not recommended for women who are breastfeeding due to potential risks. As use is generally not recommended, any consideration of this product while breastfeeding should involve specific consultation with a medical professional.

Q: Is there a pediatric formulation of Ilvico N?

A: The current oral tablet formulation of Ilvico N is contraindicated for use in children under 12 years of age. Official documents for this specific product do not list an alternative pediatric liquid or lower-dose formulation.

Q: Does Ilvico N help with sinus pressure?

A: The official therapeutic indications for the medicine include the relief of symptoms like nasal congestion. The combination of active ingredients is intended to help clear nasal and sinus congestion, which may help alleviate the feeling of pressure.

Q: Is it normal for Ilvico N to slightly raise your heart rate?

A: The medicine contains Caffeine, a stimulant, and official safety information lists palpitations (a noticeable fast or irregular heartbeat) as a potential side effect. Furthermore, use is contraindicated in patients with tachyarrhythmias (fast heart rates), indicating a potential to affect heart rhythm.

How should Ilvico N be stored and disposed of?

How to Store and Dispose of Ilvico N

Official regulatory documents define specific, mandatory conditions for storing and disposing of Ilvico N tablets to maintain quality and safety.

Storage Requirements

Temperature Constraint: The medicine must be stored at a temperature not exceeding 25°C.
Stability: The product should not be used after the expiry date (EXP) printed on the packaging, as this marks the limit of its documented stability.
Child Safety: It is mandatory to keep this medicine out of the sight and reach of children.

Disposal Instructions

Environmental Restriction: Unused or expired tablets must not be disposed of via wastewater or household waste.
Official Procedure: Patients must ask their pharmacist how to dispose of the medicine no longer required.

Ilvico N